Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
DB15616InvestigationalSmall molecule
REC-994 was cleared by the FDA in July, 2018 for a phase I trial for the treatment of cerebral cavernous malformation (CCM).
- Mechanism
- Curator reviewed
Pharmacologically active on Superoxide dismutase
- Code names
- REC-994
What you can answer from here — as of October 23, 2026
Which companies are running trials of REC-994, in which indications and phases, and which of those programs are still active?